OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cowan on Patient Eligibility Criteria for Transplant in Multiple Myeloma

July 17th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses patient eligibility criteria for transplant in multiple myeloma.

Dr. Higano on the GETUG-AFU 16 Trial Results in Prostate Cancer

July 17th 2019

Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.

Dr. Bekaii-Saab on POLO Trial Results in Pancreatic Cancer

July 17th 2019

Tanios Bekaii-Saab, MD, FACP, discusses the clinical implications of the results of the phase III POLO trial in metastatic pancreatic cancer.

Dr. Gasparetto on Safety Concerns With Venetoclax in Multiple Myeloma

July 17th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses safety concerns with venetoclax (Venclexta) in multiple myeloma.

Dr. McGregor on Unmet Needs in Advanced RCC

July 17th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses unmet needs in advanced renal cell carcinoma (RCC).

Dr. Sequist on Implications of the IMpower150 Trial in Advanced Nonsquamous NSCLC

July 17th 2019

Lecia V. Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital, discusses the implications of the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

Dr. Norden on Differences Between mCODE and Cota's CNA Network

July 16th 2019

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.

Dr. Papadimitrakopoulou on Benefits of Liquid Biopsy Versus Standard Tissue in Lung Cancer

July 16th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.

Dr. Choueiri on the Next Generation of Trials in RCC

July 16th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the next generation of trials in renal cell carcinoma (RCC).

Dr. Manji on Predictive or Prognostic Biomarkers in GI Cancers

July 15th 2019

Gulam A. Manji, MD, PhD, discusses the role of finding biomarkers in patients with gastrointestinal cancers.

Dr. Magi-Galluzzi on Preventing Overtreatment of Prostate Cancer

July 15th 2019

Cristina Magi-Galluzzi, MD, PhD, discusses the importance of properly diagnosing patients with prostate cancer to avoid overtreatment.

Dr. Girard on Rationale for PACIFIC-R Study for NSCLC

July 13th 2019

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Dr. Powles on Monitoring Immunotherapy Effects in Patients with RCC

July 13th 2019

Thomas Powles, MBBS, MRCP, MD, discusses the importance of accurately assessing the toxicity profiles of immunotherapies for renal cell carcinoma.

Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL

July 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

Dr. Choueiri on Checkpoint Inhibitors to Treat Sarcomatoid Carcinoma

July 11th 2019

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.

Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK Therapy

July 11th 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.

Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC

July 11th 2019

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).

Dr. Karmali on Challenges in MCL

July 11th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses challenges in the field of mantle cell lymphoma (MCL).

Dr. Shuch on the Impact of the SURTIME Trial in Advanced RCC

July 11th 2019

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses the impact of the phase III SURTIME study in advanced renal cell carcinoma (RCC).

Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

July 11th 2019

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.